证券代码：300436 证券简称：广生堂 公告编号：2024069 福建广生堂药业股份有限公司 关于第五届董事会第四次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 福建广生堂药业股份有限公司（以下简称"公司"）第五届董事会第四次会议 于 2024 年 10 月 21 日以邮件、电话等形式发出通知，于 2024 年 10 月 24 日在福 建省福州市闽侯县福州高新区乌龙江中大道 7 号海西高新技术产业园创新园二 期 16 号楼 12F 会议室以现场结合通讯表决方式召开。会议由董事长李国平先生 主持，会议应出席董事 9 人，实际出席董事 9 人，监事会成员列席了会议。会议 的召开符合《公司法》和《公司章程》的规定。 二、董事会会议审议情况 （一）审议通过《关于<2024 年第三季度报告>的议案》 本议案以 9 票同意、0 票反对、0 票弃权的表决结果审议通过。 本议案已经公司第五届董事会审计委员会第三次会议审议通过。 （二）审议通过《关于拟设立海外办事处的议案》 为进一步实施公司国际化战略，拓展公司药品国际化业务领域，更快 ...

Financial Performance - The company's revenue for Q3 2024 was ¥108,137,694.74, representing a 5.81% increase year-over-year, while the year-to-date revenue reached ¥326,316,366.25, up 16.67% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was -¥34,602,162.43, a decrease of 10.38% year-over-year, with a year-to-date net profit of -¥70,639,938.31, showing a significant reduction in losses by 63.93%[2]. - The basic and diluted earnings per share for Q3 2024 were both -¥0.2173, reflecting a 10.35% improvement compared to the same period last year[2]. - The total operating revenue for the third quarter of 2024 was CNY 326,316,366.25, an increase of 16.6% compared to CNY 279,691,831.64 in the same period last year[13]. - Net profit for Q3 2024 was CNY -73.76 million, an improvement from CNY -211.86 million in Q3 2023, indicating a reduction in losses of approximately 65.16%[15]. - The company reported a total comprehensive loss of CNY -73.76 million for Q3 2024, compared to a loss of CNY -211.86 million in Q3 2023, marking a decrease in comprehensive losses of approximately 65.16%[15]. - Basic and diluted earnings per share for Q3 2024 were both CNY -0.4435, an improvement from CNY -1.2295 in Q3 2023[15]. Cash Flow and Investments - The company reported a net cash flow from operating activities of -¥17,436,253.83 for the year-to-date, which is an 89.30% improvement compared to the same period last year[6]. - Cash flow from operating activities showed a net outflow of CNY -17.44 million, an improvement compared to CNY -163.01 million in the same period last year[17]. - The cash flow from investing activities for the year-to-date was -¥30,251,239.36, reflecting an 85.93% reduction in outflows compared to the previous year[6]. - Investment activities resulted in a net cash outflow of CNY -30.25 million, compared to CNY -214.99 million in the same period last year, showing a significant improvement[17]. - Cash inflow from financing activities was CNY 239 million, down from CNY 558.16 million in the previous year, indicating a decrease of approximately 57.25%[17]. - The net increase in cash and cash equivalents was -75,724,097.15 CNY, a decline from -26,479,555.68 CNY in the prior year[18]. Assets and Liabilities - The total assets as of September 30, 2024, were ¥1,514,126,207.11, down 6.22% from the end of the previous year, while the equity attributable to shareholders decreased by 13.68% to ¥445,843,242.15[2]. - The total assets decreased to CNY 1,514,126,207.11 from CNY 1,614,481,833.09, a decline of 6.2%[12]. - The total liabilities decreased to CNY 1,018,638,625.62 from CNY 1,045,236,873.62, a reduction of 2.5%[12]. - The company's cash and cash equivalents decreased to CNY 127,345,862.39 from CNY 202,830,792.87 at the beginning of the period, representing a decline of 37.1%[10]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,627[7]. - Fujian Aohua Group Co., Ltd. holds 22.02% of shares, totaling 35,068,651 shares, with 26,110,000 shares pledged[7]. - Ye Liqing, a natural person shareholder, holds 8.50% of shares, totaling 13,536,700 shares, with 10,152,525 shares under lock-up[7]. - Li Guoping holds 5.65% of shares, totaling 9,000,941 shares, with 3,100,000 shares frozen[7]. - Fujian Pingtan Aotai Technology Investment Center holds 5.04% of shares, totaling 8,025,000 shares, with 6,000,000 shares pledged[7]. - The total number of restricted shares at the beginning of the period was 23,720,749, with 1,175,718 shares released during the period[8]. - At the end of the period, the total number of restricted shares is 22,545,031[8]. - Li Guoping's restricted shares decreased from 7,920,649 to 6,750,706 after releasing 1,169,943 shares[8]. - The company has not reported any changes in the top 10 shareholders due to securities lending activities[8]. - The company has a significant portion of shares held by major shareholders under various restrictions, indicating a concentrated ownership structure[7]. Research and Development - Research and development expenses for the year-to-date were ¥22,866,899.17, a significant decrease of 75.21% compared to ¥92,260,063.89 in the same period last year, primarily due to the completion of the GST-HG171 project[5]. - The company completed the Phase II clinical trial of the innovative hepatitis B drug GST-HG141, achieving a HBV DNA suppression rate of 81.5% and 84.0% in high and low dose groups, respectively[9]. - The Phase IIa clinical trial of the oral surface antigen inhibitor GST-HG131 showed a maximum decrease in HBsAg levels of 1.07 log10 IU/ml, demonstrating significant efficacy compared to placebo[9]. - The company plans to continue focusing on innovation and product development, particularly in the area of new drug research and development[4].

福建广生堂药业股份有限公司 证券代码：300436 证券简称：广生堂 公告编号：2024067 关于控股股东拟协议转让公司部分股份的预披露公告 股东福建奥华集团有限公司保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。本公司及董事会全体成员保证公告内容 与信息披露义务人提供的信息一致。 特别提示： 1、持有福建广生堂药业股份有限公司（简称"公司"或"广生堂"）股份 35,068,651 股（占本公司总股本比例 22.02%，比例数值为四舍五入所得，下同） 的控股股东福建奥华集团有限公司（简称"奥华集团"）拟自本公告披露之日起 3 个交易日后的 3 个月内，通过协议转让方式转让本公司股份不超过 8,000,000 股（占本公司总股本比例 5.02%）。实施本次协议转让后，奥华集团持有股份占 总股本比例不低于 17.00%，仍为控股股东。本次协议转让股份事项不会导致公 司控制权发生变更，不会对公司的持续性经营产生影响。 2、本次协议转让股份事项尚未签订正式的股份转让协议，签署协议后也需 深圳证券交易所进行合规性确认后方可办理协议转让过户手续，本次协议转让能 否最终完成尚存在不确定性 ...

证券代码：300436 证券简称：广生堂 公告编号：2024066 福建广生堂药业股份有限公司 本次 GST-HG131 获得 IIa 期临床试验研究（第一组）阶段性研究结果，不 代表 IIa 期临床试验已全部成功完成并达到研究终点。公司将按照药物临床试验 相关指导原则，结合国内外临床治疗实践，组织实施好后续临床试验，并及时履 行信息披露义务。新药研发风险大、投入高、周期长，尚需开展系列临床研究并 经国家药品审评部门审批通过后方可上市，容易受到技术、审批、政策等多方面 因素的影响，其临床研究进度、研究结果及后续能否获批上市具有不确定性，存 在结果不及预期甚至临床研究失败的风险，如果最终未能通过新药注册审批，致 使研发失败，公司前期研发投入将无法回收。敬请投资者注意投资风险。 特此公告！ 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 福建广生堂药业股份有限公司（简称"公司"）乙肝治疗创新药口服表面抗 原抑制剂 GST-HG131 已完成慢性乙型肝炎（CHB）IIa 期临床试验第一组研究， 于近日第一组数据揭盲并取得阶段性研究报告，GST-HG131 取得显著优 ...

证券代码：300436 证券简称：广生堂 公告编号：2024065 福建广生堂药业股份有限公司 关于乙肝治疗创新药 GST-HG141 获得 II 期临床研究总结报告的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 福建广生堂药业股份有限公司（简称"公司"）乙肝治疗创新药 GST-HG141 已完成乙肝低病毒学症（LLV）II 期临床试验，并于近日获得 II 期临床试验的研 究总结报告，研究结果显示 GST-HG141 片对于慢性乙型肝炎低病毒血症患者具 有良好的安全性和显著药效，对 HBV DNA 的抑制效果显著优于目前临床治疗推 荐核苷（酸）类似物单药治疗对照组，在乙肝患者上确证了其在核苷（酸）类药 物治疗基础上进一步抑制 HBV DNA 复制和潜在耗竭 cccDNA 的作用，临床研究 达到预期目标，数据优异。现将有关内容公告如下： 一、基本情况 研究药物：GST-HG141 片 适应症：用于慢性乙型肝炎低病毒血症的治疗 研究项目：GST-HG141 治疗经乙肝抗病毒药物治疗的低病毒血症慢性乙型 肝炎（CHB）的随机、双盲、安慰剂对照、多中心Ⅱ期临床 ...

福建广生堂药业股份有限公司 2024 年半年度募集资金存放与使用情况的专项报告 与广生堂、中信证券股份有限公司、招商银行股份有限公司福州分行签署了《募集资金四方 监管协议》；中兴药业在中国民生银行开设募集资金专项账户，并于 2021 年 7 月 20 日与广 生堂、中信证券股份有限公司、中国民生银行股份有限公司福州分行签署了《募集资金四方 监管协议》；对募集资金的使用实行严格的审批手续，以保证专款专用；授权保荐代表人可 以随时到开设募集资金专户的银行查询募集资金专户资料，并要求保荐代表人每季度对募集 资金管理和使用情况至少进行现场调查一次。 协议相关签署时间如下： | 银行名称 | 账号 | 协议签署日期 | | --- | --- | --- | | 兴业银行股份有限公司福州环球支行 | 118110100100257142 | 2021 年 7 月 5 日 | | 招商银行股份有限公司福州分行 | 591907429610301 | 2021 年 7 月 20 日 | | 中国民生银行股份有限公司福州分行 | 632533893 | 2021 年 7 月 20 日 | 根据本公司与中信证券股份有限公司签订 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥218,178,671.51, representing a 22.93% increase compared to ¥177,488,686.44 in the same period last year[11]. - The net loss attributable to shareholders for the first half of 2024 was ¥36,037,775.88, a significant improvement of 77.08% from a loss of ¥157,216,155.35 in the previous year[11]. - The basic and diluted earnings per share improved to -¥0.2263, up 77.07% from -¥0.9871 in the previous year[11]. - The overall gross margin improved to 61.23%, an increase of 3.39 percentage points, due to cost reduction and efficiency enhancement measures[35]. - The company reported a significant reduction in income tax expenses by 91.60%, amounting to ¥1,929,369.30, due to adjustments in deferred tax assets from the previous year[47]. - The company achieved operating revenue of 218.18 million yuan, a year-on-year increase of 22.93%[35]. - The net profit attributable to shareholders was a loss of 36.04 million yuan, a significant narrowing of 77.08% year-on-year[35]. - The company reported a comprehensive income total of -36,037,775.88 CNY for the current period[143]. Cash Flow and Investments - The net cash flow from operating activities showed a substantial improvement, with a net outflow of ¥22,467,947.09, compared to a net outflow of ¥154,381,014.54 in the same period last year, marking an 85.45% reduction in cash burn[11]. - The company reported a total cash inflow from operating activities of CNY 261,635,950.34, compared to CNY 214,455,886.74 in the previous year, marking an increase of approximately 22%[138]. - The total cash outflow from operating activities was CNY 284,103,897.43, down from CNY 368,836,901.28 in the first half of 2023, reflecting a reduction of about 23%[138]. - Investment activities resulted in a net cash outflow of CNY 18,288,965.74, compared to a net outflow of CNY 158,628,456.82 in the same period last year, showing a significant reduction in investment losses[139]. - The financing activities generated a net cash outflow of CNY 31,223,518.33, a decrease from a net inflow of CNY 363,816,862.10 in the first half of 2023, indicating a shift in financing strategy[139]. Research and Development - The company aims to maintain an annual R&D investment growth of over 10% during the "14th Five-Year Plan" period, promoting technological innovation in the pharmaceutical industry[16]. - Key R&D projects include innovative drugs for hepatitis B treatment, with several in various clinical trial phases, enhancing market competitiveness in this field[35]. - Research and development expenses significantly decreased by 90.86% to ¥18,525,428.97, compared to ¥202,680,974.81 in the previous year, as the GST-HG171 project transitioned to intangible assets[47]. - The company is focusing on the development of innovative drugs for chronic HBV infection and liver health, aiming to fill industry gaps[42]. - The company is actively pursuing multiple innovative drug projects in clinical trials to improve the success rate of its R&D efforts, despite facing risks of clinical trial failures and regulatory approval delays[73]. Market and Product Development - The company is focused on developing innovative drugs for liver health, including treatments for hepatitis B, liver cancer, and COVID-19, through self-research, cooperative development, and mergers and acquisitions[18]. - The company has expanded its product line to include cardiovascular and male health products, alongside its core liver health offerings[18]. - The company has successfully launched five nucleoside antiviral drugs for hepatitis B, all of which have passed consistency evaluation, enhancing market competitiveness and accelerating the import substitution of generics[19]. - The company received a drug registration certificate for Ursodeoxycholic Acid Capsules in May 2024, with an estimated market sales of approximately CNY 2.03 billion in 2023, expected to provide new growth points upon its launch in the second half of 2024[21]. - The company is developing a new combination drug, Clopidogrel and Aspirin, which is expected to enhance antiplatelet therapy options in China, following the release of expert consensus guidelines[24]. Strategic Planning and Future Outlook - Future development strategies and operational plans are subject to market conditions and uncertainties, and do not constitute a commitment to investors[2]. - The company emphasizes the importance of risk awareness for investors regarding its future plans and forecasts[2]. - The company plans to strengthen marketing efforts and focus on market and customer needs to boost sales of new products like Tai Zhong Ding and Ursodeoxycholic Acid Capsules[35]. - The company plans to continue attracting top management and R&D talent to support its long-term growth[44]. - The company’s future outlook remains cautious due to market conditions, with no specific guidance provided for the next period[149]. Environmental and Social Responsibility - The company adheres to various environmental standards for wastewater, including a discharge limit of 400 mg/L for COD, with actual discharge measured at 17.828 mg/L[85]. - The company has implemented strict standards for air emissions, including volatile organic compounds and other pollutants[84]. - The company is committed to social responsibility, actively participating in charitable activities and supporting education and poverty alleviation initiatives[90]. - The company has received approval for changes to its self-monitoring plan for environmental protection in March 2024[84]. - The company has established a comprehensive emergency response plan for environmental incidents, with the latest revisions approved in 2022[88]. Corporate Governance and Shareholder Engagement - The company has a strong management team with extensive experience in drug development and commercialization, enhancing its operational capabilities[43]. - The company actively protects shareholder rights, particularly those of minority shareholders, by enhancing internal management and risk prevention capabilities[89]. - The company has engaged with investors over a hundred times through various channels, ensuring effective communication and safeguarding shareholder interests[89]. - The company has held multiple shareholder meetings with participation rates of 43.11% and 44.43% for the first and annual meetings, respectively, indicating active shareholder engagement[81]. - The company has committed to ensuring that its stock holdings will only be reduced according to legal requirements and regulations[92].

编制单位：福建广生堂药业股份有限公司 单位：万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上 市公司的关联 | 上市公司核算的 | 2024年期初占 | 2024年半年度占 用累计发生金额 | 2024年半年度占 用资金的利息 | 2024年半年度 偿还累计发生金 | 2024年半年度期 | 占用形成原 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关系 | 会计科目 | 用资金余额 | （不含利息） | （如有） | 额 | 末占用资金余额 | 因 | | | 控股股东、实际控制人 | | | | | | | | | | 非经营性占用 | | 及其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | | - | | 前控股股东、实际控制 | | | | | | | | | | 非经营性占用 | | 人及其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - ...

关于第五届监事会第三次会议决议的公告 证券代码：300436 证券简称：广生堂 公告编号：2024062 福建广生堂药业股份有限公司 （二）审议通过《关于<2024 年半年度募集资金存放与使用情况的专项报告> 的议案》 经核查，监事会认为：公司《2024 年半年度募集资金存放与使用情况的专 项报告》如实反映了公司 2024 年半年度募集资金存放与使用的实际情况，公司 募集资金的存放与使用情况符合《上市公司监管指引第 2 号—上市公司募集资金 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 福建广生堂药业股份有限公司（以下简称"公司"）第五届监事会第三次会 议于 2024 年 8 月 16 日以邮件、电话等形式发出通知，于 2024 年 8 月 27 日在福 建省福州市闽侯县福州高新区乌龙江中大道 7 号海西高新技术产业园创新园二 期 16 号楼 13F 会议室以通讯表决方式召开。会议由监事会主席主持，会议应到 监事 3 人，实到监事 3 人，3 名监事全部参与了表决。会议的召开符合《公司法》 和《公司章程》的规定。 二、监事会会议审议情 ...

证券代码：300436 证券简称：广生堂 公告编号：2024060 福建广生堂药业股份有限公司 关于 2024 年第三次临时股东大会决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 2、网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 8 月 16 日 9:15—9:25，9:30—11:30 和 13:00—15:00。 （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2024 年 8 月 16 日 9:15—15:00。 （一）会议召开时间： 1、现场会议召开时间：2024 年 8 月 16 日（星期五）14:00 （二）现场会议召开地点：福建省福州市闽侯县福州高新区乌龙江中大道 7 号海西高新技术产业园创新园二期 16 号楼 13F 会议室 （三）会议召集人：公司董事会 （四）会议主持人：董事长李国平先生 （五）会议召开方式：现场表决与网络投票相结合的方式 （六）会议召开 ...